H.C. Wainwright raised the firm’s price target on Shattuck Labs (STTK) to $18 from $6 and keeps a Buy rating on the shares. The firm increased its projected SL-325 probability of success to 15% from 10% based on projections for a broad positive upcoming dataset.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs: Differentiated DR3 Antagonist SL-325 Positions Company for Upside in Emerging TL1A Immunology
- Shattuck Labs management to meet with Piper Sandler
- Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’
- Shattuck Labs price target raised to $8 from $4 at Wedbush
- Shattuck Labs transferred with Buy rating at Needham